BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Official title

A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon β-1a (Avonex®) in a Rater-blinded Design

Study identification

NCT ID

NCT00605215

Recruitment status

Completed

Study type

Interventional

Phase

Phase 3

Lead sponsor

Teva Branded Pharmaceutical Products R&D, Inc.

Industry

Enrollment

1,331 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years to 55 Years

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Apr 24, 2008 (Actual)

Primary completion

Jun 10, 2011 (Actual)

Completion

Jun 10, 2011 (Actual)

Last update posted

Apr 21, 2022

2008 – 2011

United States locations

U.S. sites

36

U.S. states

23

U.S. cities

34

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 134 non-U.S. sites.